GSK has signed an agreement with the Government of Canada to supply 10,000 doses of Sotrovimab for injection, a COVID-19 monoclonal antibody therapy developed by GSK and Vir Biotechnology.
The agreement will enable provincial and territorial healthcare systems to access sotrovimab starting in October 2021 to treat patients with mild to moderate COVID-19 symptoms who are at high risk for progressing to hospitalisation or death.
The agreement includes the option for the Government of Canada to purchase additional doses in 2022 based on emerging needs.
Health Canada granted authorisation for Sotrovimab for injection in July, under its Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the treatment of mild to moderate COVID-19, confirmed by direct SARS-COV-2 viral testing, in adults and adolescents (12 years of age and older weighing at least 40 kg) who are at high risk for progressing to hospitalisation and/or death.
